NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, NF-κB is activated by proteins like COBL11 [39] and TPL2 [40], and NF-κB inhibition was shown to sensitize TKI-resistant CML cells to imatinib [41–44].